- Participant Greg Byrne, 87, from Arizona, enrolled in Moderna's melanoma vaccine trial two years ago.
An 87-year-old melanoma trial participant bought Moderna (MRNA) stock when he enrolled in an experimental mRNA cancer vaccine study two years ago, per WSJ. The stock rose more than 150% last week on successful trial results.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.